Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B
Provided By GlobeNewswire
Last update: Dec 26, 2024
– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed –
– In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity with a mean reduction of 2.9 log IU/mL in plasma HBV DNA over 28 days of treatment –
Read more at globenewswire.com
